2024/01/08 by Håkon Sætre, Marius Skow, Ingvild Vik +2 · 1 voice · 2 citations
Medicine · #Bladder and Urothelial Cancer Treatments #Urinary Bladder and Prostate Research #Urinary Tract Infections Management
paper · pdf · doi:10.3399/bjgpo.2023.0207
openalex publication_date 2024/01/08 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
BACKGROUND: Research on acute cystitis in men is scarce and treatment guidelines differ between countries. Improved antibiotic stewardship is needed. AIM: To analyse antibiotic prescriptions and outcomes of Norwegian men diagnosed with cystitis in primary care. DESIGN & SETTING: A nationwide retrospective study was undertaken in primary care in Norway. METHOD: We identified all episodes of acute cystitis in men diagnosed in Norwegian primary care during 2012-2019. Choice of antibiotic (from the Norwegian Prescription Database), treatment failure, re-prescription, and complications were stratified by age, calendar year, and risk factors. We used logistic regression to explore predefined risk factors (diabetes, prostate cancer, benign prostate hyperplasia [BPH], urinary retention, and any cancer) with complications (pyelonephritis, prostatitis, and hospitalisation) and re-prescriptions. Linear regression was used to explore time trends. RESULTS: In total, 108 994 individuals contributed 148 635 episodes. Narrow-spectrum antibiotics were first-choice treatment in 71.0% of the episodes (52.5% of all prescriptions were pivmecillinam). More than 75% of the episodes with narrow-spectrum versus 82.2% of broad-spectrum treatment did not lead to any re-prescription or complication. Complications occurred in 1.8% of all episodes (0.5% prostatitis, 0.7% pyelonephritis, and 0.7% hospitalisation). BPH was associated with increased risk of complications and re-prescription. Diabetes was associated with a lower risk of re-prescriptions. Prostate cancer and urinary retention were associated with a lower risk of both complications and re-prescriptions. CONCLUSION: Our results support narrow-spectrum antibiotics as first-line treatment. Risk factor analyses warrants further investigation.